In vitro metabolism of a rifamycin derivative by animal and human liver microsomes, whole blood and expressed human CYP3A isoform

Xenobiotica

Volumn 26, Issue 8, 1996, Pages 793-802

  Mae, T ^a   Hosoe, K ^a   Fujii, K ^a   Yamashita, K ^a   Yamane, T ^a   Hidaka, T ^a   Ohashi, T ^a  

^a KANEKA CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; RIFAMYCIN DERIVATIVE;

ANIMAL TISSUE; ARTICLE; BLOOD; CONTROLLED STUDY; DOG; DRUG METABOLISM; GUINEA PIG; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER METABOLISM; LIVER MICROSOME; MALE; MONKEY; MOUSE; NONHUMAN; NORMAL HUMAN; RAT; SPECIES DIFFERENCE;

EID: 0029822605     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.3109/00498259609046749     Document Type: Article

References (26)

1. AOYAMA, T., GELBOIN, H. V., and GONZALEZ, F. J., 1990, Mutagenic activation of 2-amino-3-methylimidazo[4,5-f]quinoline by complementary DNA-expressed human liver P-450. Cancer Research, 50, 2060-2063.
2. 14C-rifabutin in animals and man. Journal of Antimicrobial Chemotherapy, 26, 813-822.
3. COCCHIARA, G., STOROLIN BENEDETTI, M., VICARIO, G. P., BALLABIO, M., GIOIA, B., VIOGLIO, S., and VIGEVANI, A., 1989, Urinary metabolites of rifabutin, a new antimycobacterial agent, in human volunteers. Xenobiotica, 19, 769-780.
4. CRESPI, C. L., PENMAN, B. W., LEAKEY, J. A. E., ARLOTTO, M. P., STARK, A., PARKINSON, A., TURNER, T., STEIMEL, D. T., RUDO, K., DAVIES, R. L., and LANGENBACH, R., 1990, Human cytochrome P450IIA3: cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450IIE1. Carcinogenesis, 11, 1293-1300.
5. CZERWINSKI, M., MCLEMORE, T. L., PHILPOT, R. M., NHAMBURO, P. T., KORZEKWA, K., GELBOIN, H. V., and GONZALEZ, F. J., 1991, Metabolic activation of 4-ipomeanol by complementary DNA-expressed human cytochromes P-450: evidence for species-specific metabolism. Cancer Research, 51, 4636-4638.
6. DONATO, M. T., GOMEZ-LECHON, M. J., and CASTELL, J. V., 1993, A microassay for measuring cytochrome P450IA1 and P450IIB1 activities in intact human and rat hepatocytes cultured on 96-well plates. Analytical Biochemistry, 213, 29-33.
7. EMORI, M., SAITO, H., SATO, K., TOMIOKA, H., SETOGAWA, T., and HIDAKA, T., 1993, Therapeutic efficacy of benzoxazinorifamycin KRM-1648 against experimental Mycobacterium avium infection induced in rabbits. Antimicrobial Agents and Chemotherapy, 37, 722-728.
8. FUJII, K., TSUJI, A., MIYAZAKI, S., YAMAGUCHI, K., and GOTO, S., 1994, In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives. Antimicrobial Agents and Chemotherapy, 38, 1118-1122.
9. GONZALEZ, F. J., and KORZEKWA, K. R., 1995, Cytochromes P450 expression systems. Annual Review of Pharmacology and Toxicology, 35, 369-390.
10. HOSOE, K., KONISHI, E., HIDAKA, T., YAMANE, T., YAMASHITA, K., and OHASHI, T., 1994, High-performance liquid chromatographic determination of 3′-hydroxy-5′-(4-isobutyl-1-piperazinyl)-benzoxazinorifamycin (KRM-1648) and its deacetyl metabolite in plasma, whole blood, urine and tissue samples in rats. Journal of Chromatography B, 653, 177-186.
11. HOSOE, K., MAE, T., YAMASHITA, K., FUJII, K., YAMANE, T., HIDAKA, T., and OHASHI, T., 1996, Identification and antimicrobial activity of urinary metabolites of a rifamycin derivative in dog. Xenobiotica 26, 321-332.
12. IMAI, Y., ITO, A., and SATO, R., 1966, Evidence for biochemically different types of vesicles in the hepatic microsomal fraction. Journal of Biochemistry, 60, 417-428.
13. IMAOKA, S., TERANO, Y., and FUNAE, Y., 1989, Expression of four phenobarbital-inducible cytochrome P-450s in liver, kidney, and lung of rats. Journal of Biochemistry, 105, 939-945.
14. INDERLIED, C. B., BARBARA-BURNHAM, L., WU, M., YOUNG, L., and BERMUDEZ, L., 1994, Activity of the benzoxazinorifamycin KRM-1648 against the Mycobacterium avium complex in vitro and in macrophages. Antimicrobial Agents and Chemotherapy, 38, 1838-1843.
15. KLEMENS, S. P., GROSSI, M. A., and CYNAMON, M. H., 1994, Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model. Antimicrobial Agents and Chemotherapy, 38, 2245-2248.
16. KUZE, F., YAMAMOTO, T., AMITANI, R., and SUZUKI, K., 1991, In vitro activities of new rifamycin derivatives against mycobacteria. Kekkaku, 66, 7-12.
17. LUNA-HERRERA, J., REDDY, M. V., and GANGADHARAM, P. R. J., 1995, In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli. Antimicrobial Agents and Chemotherapy, 39, 440-444.
18. NELSON, D. R., KOYMANS, L., KAMATAKI, T., STEGEMAN, J. J., FEYEREISEN, R., WAXMAN, D. J., WATERMAN, M. R., GOTOH, O., COON, M. J., ESTABROOK, R. W., GUNSALUS, I. C., and NERBERT, D. W., 1996, P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 6, 1-42.
19. OMURA, T., and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes. Journal of Biological Chemistry, 239, 2379-2385.
20. SAITO, H., TOMIOKA, H., SATO, K., EMORI, M., YAMANE, T., YAMASHITA, K., HOSOE, K., and HIDAKA, T., 1991, In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins. Antimicrobial Agents and Chemotherapy, 35, 542-547.
21. SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y., and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414-423.
22. TAINAKA, H., HATANAKA, T., and ONO, S., 1995, Use of human P450 expression system in studies of xenobiotic metabolism. Xenobiotic Metabolism and Disposition, 10, 420-425.
23. TOMIOKA, H., SAITO, H., SATO, K., YAMANE, T., YAMASHITA, K., HOSOE, K., FUJII, K., and HIDAKA, T., 1992, Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice. Antimicrobial Agents and Chemotherapy, 36, 387-393.
24. VIGEVANI, A., BALLABIO, M., GIOIA, B., MARSILI, L., VIOGLIO, S., and FRANCESCHI, G., 1985, Identification of urinary metabolites of rifamycin LM 427 in man. Journal of Antibiotics, 38, 1799-1802.
25. YAMAMOTO, T., AMITANI, R., KUZE, F., and SUZUKI, K., 1990, In vitro activities of new rifamycin derivatives against Mycobacterium tuberculosis and M. avium complex. Kekkaku, 65, 805-810.
26. YAMANE, T., HASHIZUME, T., YAMASHITA, K., KONISHI, E., HOSOE, K., HIDAKA, T., WATANABE, K., KAWAHARADA, H., YAMAMOTO, T., and KUZE, F., 1993, Synthesis and biological activity of 3′-hydroxy-5′-aminobenzoxazinorifamycin derivatives. Chemical and Pharmaceutical Bulletin, 41, 148-155.